Don Healey
Chief Scientific Officer
Life Sciences
Acer Therapeutics
United States of America
Biography
Dr. Healey has over 25 years experience in cellular immunology and immune regulation in both academic and biotech environments. Prior to joining Opexa in April 2010, Dr. Healey was Director of Immunology for Argos Therapeutics, and was responsible for the development of novel autologous dendritic cell therapies for the treatment of renal carcinoma and HIV; both products are currently in Phase II clinical trials. Dr Healey was Group Leader for Immunotherapy for ML Laboratories, UK, (formerly Cobra Biotherapeutics) where he developed autologous dendritic cell therapies for the treatment of Melanoma.
Research Interest
He developed autologous dendritic cell therapies for the treatment of Melanoma.
